Topics

KALA Strides, NKTR Plunges, RMTI In Deal With Sun Pharma, DRRX Faces FDA Panel

20:53 EST 15 Jan 2020 | RTTNews

Today's Daily Dose brings you news about Kala Pharma's completion of enrollment in STRIDE 3 trial, Rockwell Medical's license and supply agreements with India-based Sun Pharmaceutical and upcoming regulatory catalyst of DURECT.

Original Article: KALA Strides, NKTR Plunges, RMTI In Deal With Sun Pharma, DRRX Faces FDA Panel

NEXT ARTICLE

More From BioPortfolio on "KALA Strides, NKTR Plunges, RMTI In Deal With Sun Pharma, DRRX Faces FDA Panel"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...